Foundation Medicine will develop a companion diagnostic test for use with a Clovis Oncology drug now in mid-stage clinical trials to treat patients with ovarian cancer.
Foundation Medicine recently revealed plans to raise up to $150 million in a secondary offering to fuel R&D and announced on Thursday that it is teaming up with Clovis Oncology to develop an innovative companion diagnostic for ovarian cancer.
Cancer diagnostics wunderkind Foundation Medicine has revealed plans to raise as much as $150 million in a secondary offering to fuel domestic and international expansion and the development of new products to keep the growth engine running.
Investors drove Foundation Medicine's stock up more than 10% during late morning trading on Feb. 26. What got them moving? They responded to news that the cancer diagnostic darling continued to grow revenue at a healthy clip as 2013 came to a close.
The recently IPO'd Foundation Medicine has expanded its relationship with Novartis, lending out its gene-profiling technology to help the drugmaker develop cancer treatments.
Diagnostics luminary Foundation Medicine has expanded its relationship with pharma giant Novartis, giving the drugmaker more access to its gene profiling technology to develop cancer treatments.
Foundation Medicine is touting some promising new data highlighting the utility of its signature diagnostic technology for blood cancers, news that will help the newly public Massachusetts startup maintain development and commercial momentum.
Cancer diagnostics darling Foundation Medicine released its first quarterly numbers as a public company, and they show encouraging revenue gains as the Massachusetts outfit pursued a rapid sales expansion for its debut product.
Last year when we did the list of the top 10 biotech IPOs of 2012, we were lucky to have 10. Actually, there were 11, and that looked pretty good compared to the lean and hungry years of 2008 to...
Despite renewed investor fervor and no shortage of promising technologies, medical device outfits had so far been largely loathe to join in on the biotech IPO revival. Now that LDR has bagged an over-allotted, top-of-its range debut, is it time for med tech's big moment?